Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT.
Lee
H J
HJ
Gulbis
A
A
De Padua Silva
L
L
Hosing
C
C
Khouri
I
I
de Lima
M
M
Champlin
R E
RE
Ciurea
S O
SO
D000017:ABO Blood-Group System / Q000276:immunology; D000368:Aged; D000743:Anemia, Hemolytic / Q000188:drug therapy* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000276:immunology*; D001787:Blood Group Incompatibility / Q000276:immunology*; D001803:Blood Transfusion; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015477:Leukemia, Myelomonocytic, Chronic / Q000628:therapy; D000069283:Rituximab; D013577:Syndrome; D014184:Transplantation, Homologous
D000017:ABO Blood-Group System; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab